Grail blood test shows promise in early detection of lung cancer

CHICAGO, June 2 (Reuters) - An experimental blood screening test from Grail Inc showed early promise in detecting early-stage lung cancers based on free-floating DNA released by tumors, according to preliminary results released on Saturday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.